Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15877800 | 1.00 | BRD4 (0.42) | BRD4BTKKMT2ANPC1RAB9A | |
| SCHEMBL15894484 | 1.00 | BRD4 (0.42) | BRD4BTKKMT2ANPC1RAB9A | |
| SCHEMBL15878525 | 0.82 | POLB (0.47) | BTKKMT2APOLBGAANPSR1 | |
| SCHEMBL15894485 | 0.82 | POLB (0.47) | BTKKMT2APOLBGAANPSR1 | |
| SCHEMBL15878527 | 0.82 | POLB (0.47) | BTKKMT2APOLBGAANPSR1 | |
| SCHEMBL15878526 | 0.82 | POLB (0.47) | BTKKMT2APOLBGAANPSR1 | |
| SCHEMBL2944277 | 0.79 | BRD4 (0.41) | BRD4BTKKMT2ANPC1RAB9A | |
| SCHEMBL2944275 | 0.79 | BRD4 (0.41) | BRD4BTKKMT2ANPC1RAB9A | |
| SCHEMBL15877933 | 0.79 | KMT2A (0.51) | BRD4BTKKMT2ANPC1RAB9A | |
| SCHEMBL15894489 | 0.79 | KMT2A (0.51) | BRD4BTKKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240543-B1 | BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-2948458-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20180118766-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3240543-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| US-9481682-B2 | Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| WO-2016109216-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20150353570-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2948458-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014114185-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014113932-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| US-20140206681-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118766-A1 | BTK INHIBITORS | BTK, SYK, LYN | BRD4 490/4885BTK 1/4885KMT2A 1263/4885 |
| US-20140206681-A1 | BTK INHIBITORS | BTK, SYK, LYN | BRD4 429/4885BTK 1/4885KMT2A 1175/4885 |
| US-20150353570-A1 | BTK INHIBITORS | BTK, SYK, LYN | BRD4 429/4885BTK 1/4885KMT2A 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.